Aderibigbe, BANaki, TSteenkamp, VNwamadi, MRay, Suprakas SBalogun, Mohammed OMatshe, William MR2019-10-292019-10-292019-09Aderibigbe, B.A. et al. 2019. Physicochemical and in vitro cytotoxicity evaluation of polymeric drugs for combination cancer therapy. International Journal of Polymeric Materials and Polymeric Biomaterials, pp.150091-40371563-535Xhttps://doi.org/10.1080/00914037.2019.1667802https://www.tandfonline.com/doi/full/10.1080/00914037.2019.1667802http://hdl.handle.net/10204/11199Copyright: 2019 Taylor & Francis. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website. International Journal of Polymeric Materials and Polymeric Biomaterials, pp.15Platinum-based drugs are potent anticancer drugs and are effective for the treatment of various cancers. However, they are limited pharmacologically due to toxic side effects, drug resistance and poor water solubility. In order to overcome these limitations, platinum was incorporated onto polyamidoamine carriers together with alendronate and procaine hydrochloride to form a series of conjugates. Cytotoxicity was assessed using the sulforhodamine B assay on MCF-7, MDA-MB-231 and EA.hy926 cell lines. The polymer-drug conjugates showed cytotoxicity which was selective to the cancer cell lines. The free drugs decreased cell density in all cell lines and were nonspecific. These findings indicate that the incorporation of bioactive agents onto polymers can overcome cytotoxicity associated with the drugs. The selective inhibitory effects of the conjugates towards the cancer cell lines suggest that these conjugates are potential therapeutics for combination therapy.enAlendronateCytotoxicityPlatinumPolyamidoaminePolymer-drug conjugatesProcaineArticleAderibigbe, B., Naki, T., Steenkamp, V., Nwamadi, M., Ray, S. S., Balogun, M. O., & Matshe, W. M. (2019). Physicochemical and in vitro cytotoxicity evaluation of polymeric drugs for combination cancer therapy. http://hdl.handle.net/10204/11199Aderibigbe, BA, T Naki, V Steenkamp, M Nwamadi, Suprakas S Ray, Mohammed O Balogun, and William MR Matshe "Physicochemical and in vitro cytotoxicity evaluation of polymeric drugs for combination cancer therapy." (2019) http://hdl.handle.net/10204/11199Aderibigbe B, Naki T, Steenkamp V, Nwamadi M, Ray SS, Balogun MO, et al. Physicochemical and in vitro cytotoxicity evaluation of polymeric drugs for combination cancer therapy. 2019; http://hdl.handle.net/10204/11199.TY - Article AU - Aderibigbe, BA AU - Naki, T AU - Steenkamp, V AU - Nwamadi, M AU - Ray, Suprakas S AU - Balogun, Mohammed O AU - Matshe, William MR AB - Platinum-based drugs are potent anticancer drugs and are effective for the treatment of various cancers. However, they are limited pharmacologically due to toxic side effects, drug resistance and poor water solubility. In order to overcome these limitations, platinum was incorporated onto polyamidoamine carriers together with alendronate and procaine hydrochloride to form a series of conjugates. Cytotoxicity was assessed using the sulforhodamine B assay on MCF-7, MDA-MB-231 and EA.hy926 cell lines. The polymer-drug conjugates showed cytotoxicity which was selective to the cancer cell lines. The free drugs decreased cell density in all cell lines and were nonspecific. These findings indicate that the incorporation of bioactive agents onto polymers can overcome cytotoxicity associated with the drugs. The selective inhibitory effects of the conjugates towards the cancer cell lines suggest that these conjugates are potential therapeutics for combination therapy. DA - 2019-09 DB - ResearchSpace DP - CSIR KW - Alendronate KW - Cytotoxicity KW - Platinum KW - Polyamidoamine KW - Polymer-drug conjugates KW - Procaine LK - https://researchspace.csir.co.za PY - 2019 SM - 0091-4037 SM - 1563-535X T1 - Physicochemical and in vitro cytotoxicity evaluation of polymeric drugs for combination cancer therapy TI - Physicochemical and in vitro cytotoxicity evaluation of polymeric drugs for combination cancer therapy UR - http://hdl.handle.net/10204/11199 ER -